Company Overview
Snapshot
Founded in April 2018 by Alon Shalev and Prof. Natan, QART Medical operates with 1–10 employees. The company has secured funding across four rounds from four investors, with its last funding round occurring in March 2024.
Business overview
QART Medical is a clinical-stage company developing a solution for highly informative characterization and selection of sperm cells for in vitro fertilization (IVF). The company's core technology is a compact, stand-alone benchtop clinical workstation that utilizes a built-in quantitative phase interferometric microscopy (IPM) imaging platform and a microfluidics sorting stage. This system aims to improve IVF success rates by quantitatively characterizing the morphology and contents of individual sperm cells with stain-free, real-time 3D topographic imaging, providing quantitative DNA integrity information on a cell-by-cell basis and automatically sorting semen samples. QART Medical serves the healthcare industry, particularly clinics and hospitals focused on fertility and women's health, operating within the Health Tech & Life Sciences sector.
Strategic signal
In February 2025, news reports highlighted that Tel Aviv University's technology, which forms the basis of QART Medical's system, has demonstrated the potential to double IVF success rates. This signals a significant validation of QART Medical's underlying scientific approach and its potential to revolutionize fertility treatments. For investors, this indicates strong clinical promise and a potential for substantial market impact in addressing male factor infertility and improving IVF outcomes.
Log in to access full profile ›Company Intelligence Q&A
- What is QART Medical's primary focus?
- QART Medical is a clinical-stage company developing a solution for highly informative characterization and selection of sperm cells for in vitro fertilization (IVF).
- When was QART Medical founded?
- QART Medical was founded in April 2018.
- What is the core technology behind QART Medical's system?
- The QART system is based on a built-in quantitative phase interferometric microscopy (IPM) imaging platform with a microfluidics sorting stage, designed for stain-free, real-time 3D topographic imaging of individual sperm cells.
- Which investor participated in QART Medical's Seed funding round in September 2020?
- In September 2020, The Chartered Group led a Seed funding round for.
- What significant development was reported in February 2025 regarding the technology behind QART Medical?
- In February 2025, it was reported that Tel Aviv University technology, which QART Medical utilizes, has been shown to double IVF success rates.